Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib +/- TMZ in Recurrent Glioblastoma
NCT00727506Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2008
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of afatinib in glioblastoma multiforme (GBM), sponsored by Boehringer Ingelheim. Started Jul 2008; status: completed.
02
Drugs
afatinib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00727506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00727506.